ASK REDCHAT ANYTHING ABOUT FOGHORN THERAPEUTICS INC.
Foghorn Therapeutics Inc. (NASDAQ: FHTX)
Listen to this Section
$5.95
-0.0050
(
-0.08% )
0.1K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| FHD-286 + decitabine or low-dose cytarabine (LDAC)DetailsMyelodysplastic syndrome, Acute myeloid leukemia, Cancer |
Phase 1 |
| FHD-909DetailsCancer, Non-small cell lung carcinoma |
Phase 1 |
| FHD-286DetailsMetastatic Uveal Melanoma |
Failed |
| FHD-609DetailsSynovialsarcoma, Sarcoma |
Failed |
Market Data
|
| Open |
$5.95 |
| Previous Close |
$5.95 |
| Volume |
0.1K |
| Market Cap |
$349.35M |
| Day Range |
$5.95 - $5.95 |
| 52 Week Range |
$3.27 - $6.95 |
| Shares Outstanding |
58.71M |
| Change % |
-0.08% |
| Net Change |
▼ -0.0050 |
| Insider Ownership |
-0.03% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Medicinal Chemicals and Botanical Products |
| IPO Year | 2020 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-12,360.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-09-13 |
Sale |
0.00 |
Agresta Samuel |
| 2023-09-13 |
Sale |
-272000.00 |
Cardama Alfonso Quintas |
| 2023-08-18 |
Sale |
-311297.00 |
Agresta Samuel |
| 2023-08-18 |
Sale |
-63000.00 |
GOTTSCHALK ADRIAN |